Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More nonsmokers are getting lung cancer: Oncologist explains why

2.

FDA Approves CAR-T Product Use for Myeloma Early.

3.

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

4.

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

5.

ALK-positive lung cancer trial results show unprecedented progression-free survival.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot